Journal of Pharmacovigilance · 2014 · 30 citations · 40 references
PharmacyPharmacologyPharmacotherapyBioavailabilityClinical PharmacologyMedication Safety PolicyAdverse Drug Reaction ReportingBlood-brain Barrier PharmacologyCognitive ImpairmentDrug Safety MonitoringLipid-lowering TherapyPharmacoepidemiologyBlood-brain Barrier PermeabilityCognitive Adverse EffectsCognitive EffectsCognitive PerformanceCognitive Performance ImpairmentFda RegulationProportional Reporting RatioStatin Adverse Effects
The ACC/AHA released new guidelines in December of 2013 for treatment of high blood cholesterol to simplify identification and treatment of patients most likely to benefit from statins. These guidelines may result in more patients receiving statin therapy, and at younger ages. In 2012, the U.S. Food and Drug Administration (FDA) mandated warnings for all statin drugs for possible adverse effects on cognitive performance. Statins can be classified as having greater lipophilic or hydrophilic solubility properties with lipophilic statins more readily crossing the blood brain barrier, and possibly differentially inducing detrimental cognitive effects.
40
Heart Disease and Stroke Statistics—2012 Update
Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2011 · 7.2K citations · Full text
Heart Disease and Stroke Statistics—2011 Update
Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2010 · 6.2K citations
Statins and the risk of dementia
Hershel Jick, GL Zornberg, Sudha Seshadri et al. · The Lancet · 2000 · 1.8K citations